News

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused…

1 year ago

Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform

Company Will Pursue Drug Discovery of Market-Authorized, Finished Pharmaceuticals that Address Demand for Personalized TherapiesFRANKFURT AM MAIN, Germany, Nov. 15,…

1 year ago

Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update

-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median…

1 year ago

Greater risk impact on businesses predicted as once-in-century climate events now happen yearly

BOSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- HX Global, the US division of Healix International, a global leader in medical,…

1 year ago

Lifecore Biomedical Announces Completion of Corporate Name Change

Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR” Lifecore global headquarters relocated to Chaska, MN…

1 year ago

Clearday To Provide Robotic Services To Skilled Nursing Facilities

San Antonio, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearday (OTCQX: CLRD) is pleased to announce that Chandler Hall Health…

1 year ago

Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov.…

1 year ago

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on…

1 year ago

Smart for Life Announces Q3 2022 Financial Results

Revenue Increases 59.1% Year-Over-Year to $5.4 Million for the Third Quarter of 2022 Due to Successful Acquisition Strategy Gross Profit…

1 year ago

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for…

1 year ago